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Poster Session-II 151of drug, alcohol, or tobacco use; caregiver concerns; psychiatric di-
agnosis; a patient history of no-compliance; the stress of this intense
treatment option becomes escalated for all involved. Such factors can
lead to complications during the transplant course including longer
hospital stays, increased stress to the patient, caregiver, and health-
care team, increase ethical issues, and subsequent poorer outcomes.
Early identification of such factors permits development of a plan of
care to facilitate optimal treatment courses. The SCTNurse plays an
important role in identifying and addressing these issues.
Intervention: A quality improvement process was developed to
help identify confounding factors and address them prior to treat-
ment. An algorithm, including a multidisciplinary care conference
(CC), provides a process flow for the healthcare team to follow.
When an issue is identified by any member of the outpatient health-
care team, a CC is requested. Participants of CC include Physician,
APN, SocialWorker, Clinical Ethicist, Advocacy, and Clinic and In-
patient Nurse; with optional members including Adolescent Young
Adult, Psychiatry and Chaplaincy. The goal of the CC is to discuss
concerns with the patient, answer patient/caregivers questions, and
promote communication across the care continuum.
Results: The result of this process is the development of an indi-
vidualized plan of care that may include postponement of transplant,
substance abuse programparticipation, care contracts, and/or formal
ethics consult. A case study will be presented that highlights how the
use of this process has lead to improved patient outcomes. Recom-
mendations The implementation of this or a similar process in any
SCT program will help facilitate the proactive identification of con-
cerns and promote patients safely going forward with treatment.428
BLOOD AND MARROW TRANSPLANT TELEPHONE TRIAGE: DEVELOP-
MENT OF A DOCUMENTATION TOOL TO ASSIST WITH CONCISE INFOR-
MATION GATHERING
Ensley, L.A., Powell, S., Anderson-Reitz, L. Baylor Charles A Sammons
Cancer Center, Dallas, TX
Purpose/Background: Blood and marrow transplant patients
present complicated issues throughout the transplant process. Post
allograft patients can have complications long after the initial trans-
plant period. Out-patient transplant recipients often present acute
issues that may require admission to an in-patient setting. Registered
nurses are presented with the challenge of assessment and triage of
these complicated patients by telephone communication. The need
for a concise communication and documentation tool was identified
to assist with both information gathering and formulating amedically
directed plan.
Intervention: This center has a designated telephone line for pa-
tient ‘‘sick calls’’. Patients or caregivers are directed to utilize this line
for any medical issues. We have developed a tool specific to blood
and marrow transplant issues and complications. The tool helps
the registered nurse concisely collect and document information
provided by the patient or caregiver. This tool is then utilized to
communicate these issues to the medical staff for a medical plan
that is documented on the tool. The tool is currently being utilized
within a pilot period for six months.
Evaluation: The tool will be evaluated at the end of six months.
Additions or deletions will then bemade to the tool. Continued eval-
uation of the tool will then be made on a yearly basis.
Discussion: Utilization of a regimented documentation tool will
assist with prompting the nurse in phone assessment and triage and
will allow for more concise reporting to the medical staff and ulti-
mately better plans of care.429
ASSOCIATION OF HEMATOPOIETIC STEM CELL PRODUCT CULTURE AND
CLINICAL INFECTION IN PATIENTS RECEIVING MYELOABLATIVE CHE-
MOTHERAPYWITH AUTOLOGOUS HEMATOPOIETIC STEM CELL REINFU-
SION
Cervone, K., Cartwright, F., Gardner, S. NYU Medical Center, New
York, NY
Purpose: The purpose of this descriptive retrospective QA pro-
ject is to examine the association between hematopoietic progenitorcell (HPC) product cultures at the time of reinfusion and the subse-
quent development of infection.
Methods:Using a descriptive, retrospective design, data were col-
lected from the records of 68 patients who received autologous pe-
ripheral blood HPC reinfusions after undergoing myeloablative
chemotherapy at a single institution. Consistent with the oncology
service QA program, all of the products were tested for microbial
contamination at the time of stem cell processing. At the time of re-
infusion, a sample from each thawed product was sent to the micro-
biology lab. Following theHPC reinfusion, blood cultures were sent
on patients at the time of their first fever and at least once daily until
they were afebrile and cultures were negative. Blood cultures were
sent from each lumen of the central venous catheter. Peripheral
blood cultures were not routinely drawn.
Results: Between March 2002 and September 2008, 68 patients
received 148 HPC reinfusions. All of the reinfused HPC products
were negative for bacterial contamination at the time of processing.
Nineteen of the reinfused HPC cultures, which were reinfused into
13 patients, were positive. Two of these patients developed positive
blood cultures. Patient #1 had HPC product culture positive for
Bacillus species and Staphhylococcus epidermis. Blood cultures
were positive only for S. epidermis on day 115. Patient #2 had
HPC product cultures positive for Streptococcus oralis. Blood
cultures were positive for Streptococcus mitis on day 14 and S.
epidermis on day 16.
Conclusions: There does not appear to be a strong correlation
between positive product cultures and the subsequent development
of positve blood cultures. Microbial testing at the time of HPC
reinfusion may not be necessary.430
PNEUMOCYSTIS CARINII PNEUMONIA (PCP) PROPHYLAXIS PROTOCOL
AFTER AUTOLOGOUS TRANSPLANTS: A RETROSPECTIVE REVIEW AT A
REGIONAL TRANSPLANT CENTER
Ramey, S.1, Bohnenblust, E.1, Smalling, D.1, Schisler, N.1,
Thompson, L.1, Schammel, C.1, Dillard, T.2, Fanning, S.2, Webb, S.2
1Furman University, Greenville, SC; 2Cancer Centers of The Carolinas,
Greenville, SC
Autologous hematopoeitic stem cell transplantion is an effective
treatment option for many hematological diseases. The morbidity
associated with this treatment, however, is often related to the in-
creased risk of infection following transplant due to an immunocom-
promised host. Prophylactic care designed to prevent infection varies
widely among institutions. In this retrospective analysis, we reviewed
the prophylactic protocol for Pneumocystis carinii pneumonia (PCP)
at Cancer Centers of the Carolinas (CCC), a regional transplant cen-
ter. All autologous hematopoietic stem cell transplants completed
for hematologic disorders between 2002 and 2007 (n 5 150) were
reviewed with regard to prophylactic Bactrim administration. The
standard operating procedure at CCC utilized Bactrim at a dose of
one double strength tab BID on Saturday and Sunday each week.
Protocol guidelines suggest prophylactic Bactrim initiation fourteen
days post transplant, continuing minimally through day 1200. At
day 200, the peripheral blood CD4 count was assessed. A CD4 count
of .200 cells/mliter prompted Bactrim discontinuation. Per proto-
col, values lower than this threshold necessitated CD4 count reas-
sessment at 100-day intervals until the threshold was achieved.
Results revealed 69% of patients were tested to threshold while
28% of patients were not tested to threshold. Of patients who
reached threshold, 76% had done so by d1260. The median 200
day post-transplant CD4 count assessed was 232 cells/mliter. The
number of days to reach threshold was not significantly different
when considering gender, race, or primary disease. However,
patients with multiple myeloma requiring tandem transplantion re-
sulted in significant delays in reaching threshold with non-tandem
patients reaching threshold in a median time of 200 days and tandem
patients reaching threshold in a median time of 282 days. These
results verify that, per protocol, d1200 is a valid point to initiate
assessment of CD4 count recovery following single autologous
transplantion. Patients having reached the threshold at this time
can discontinue Bactrim prophylaxis, and thus eliminate any
potential for Bactrim-associated side effects. Patients with CD4
counts below threshold at initial testing remain at risk for PCP
152 Poster Session-IIand therefore require continued prophylaxis until CD4 count recov-
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PROPHYLAXIS FOR HERPETIC VIRUSES POST AUTOLOGOUS STEM CELL
TRANSPLANTS: A RETROSPECTIVE REVIEW AT A REGIONAL TRANS-
PLANT CENTER
Bohnenblust, E.1, Ramey, S.1, Schisler, N.1, Thompson, L.1,
Schammel, C.1, Dillard, T.2, Fanning, S.2, Webb, S.2 1Furman Univer-
sity, Greenville, SC; 2Cancer Centers of the Carolinas, Greenville, SC
Following hematopoietic stem cell transplantation as a treatment
for hematological disease, prophylactic care for herpetic infections in
immunocompromised patients is essential. Acyclovir is a widely pre-
scribed anti-viral medication that can reduce the risk of HSV, CMV,
EBV, and VZV reactivation in post-transplant patients. The benefits
of acyclovir include low cost and low toxicity. However, the usage,
dosage, and duration of acyclovir treatment vary among treatment
centers. To evaluate the efficacy of one acyclovir prophylaxis proto-
col, we performed a retrospective review from 2002–2007 of all pa-
tients (n 5 150) who underwent single or tandem autologous
peripheral blood stem cell transplantations at the Cancer Centers
of the Carolinas (CCC). The CCC’s standard operating procedure
suggests that patients receive 400 mg of acyclovir BID three times
per week following transplantation until the patient’s CD4 count
reaches the 400 cells/mliter threshold. CD4 count testing began at
200 days with subsequent tests every 100 days until patients reached
threshold. Only 19% of patients were tested to threshold in this
study. Acyclovir prophylaxis was terminated prior to threshold in
30% of patients. CD4 counts performed at 200 days post transplant,
had a median value of 232 cells/mliter. Within the 28 patient cadre
that were monitored for CD4 counts, 53% reached threshold within
199 days, 67%within 299 days, and 82%within 399 days post-trans-
plantation. The remaining 17% reached threshold 400 or more days
post-transplantation. These results suggest reassessment of the CD4
count threshold at critical time junctures in the reconstitution of the
immune system is necessary to avoid indefinite acyclovir therapy. A
myriad of issues influence patient compliance and provider response
to results. Some of these factors include patient non-compliance, in-
complete testing, results not available for office visits andmanual sys-
tems for ordering and analysis. The conclusion of this study focuses
on areas for process improvement.With the development of a FACT
compliant EMR (Electronic Medical Record), our center will create
transplant specific triggers to assure appointments are made and re-
sults obtained for provider assessment. Additional data pointsmay be
developed to track HSV, VZV, CMV and EBV antibody status as
well as the incidence of relevant viral infections and concomitant an-
tiviral therapy. Computerized results will allow on-going tracking,
follow-up and analysis.432
SYMPTOMS AND PERSONALITY TRAITS IN PATIENTSWITH HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION
Na, Y.H.1, Yoo, M.H.1, Han, E.K.1, Lee, J.Y.1, Seo, G.E.1, Lee, J.H.1,
Song, B.E.2, Kim, K.S.1 1St. Mary’s Hospital, Seoul, Korea; 2Catholic
Medical Center, Seoul, Korea
The purpose of this study is to investigate the personality of pa-
tients with HSCT, to identify the symptom experience shown by pe-
riods of transplantation, and to present basic database in order to
formulate more effective, optimum nursing interventions for
HSCT. The subjects of this study were 100 patients who were 18
years of age and older and underwent HSCT at the HSCT center
in S Hospital of C University located in Seoul. The data were col-
lected between October 1, 2007 and August 15, 2008. The personal-
ity trait was measured once at the next day of hospitalization for
transplantation, by using of the shortened version of NEO-PI-R,
which was translated and adapted in Korean. The symptom experi-
ence was investigated three times ‘pre-transplant stage(T1)’, ‘trans-
plant stage(T2)’ and ‘post-transplant stage(T3)’ of HSCT for each
subject, by using of a tool translated and adapted in Korean from
Symptom Occurrence(Frequency), Intensity & Distress-Stem Cell
Transplantation (SFID–SCT). The results of this study are as fol-lows; Over 80% of the patients showed changes in taste, loss of ap-
petite, mouth dryness, fatigue, diarrhea, nausea, insomnia, and
mouth sores in the period of T2. Changes in taste and loss of appetite
were highest in the scores of symptom occurance(SO), while changes
in taste were highest in the scores of symptom distress(SD). As for
the personality factors of the patients withHSCT, the score of agree-
ableness was highest. There was no significant difference in person-
ality traits according to the types of transplantation and disorders.
Among the five personality factors of the patients with HSCT, neu-
roticism and extraversion affected the symptoms. Neuroticism as
a factor affected almost all the periods of transplantation for the
symptom intensity(SI) and SD, except the SI of T3. Extraversion af-
fected all the periods of transplantation for the SI and SD. Conclu-
sively, the SO, SI and SD were highest in T2, and the neuroticism
and extraversion among the personality traits of the patients with
HSCT affected the symptoms. Therefore, it is necessary to develop
nursing interventions appropriate for patients who had higher neu-
roticism and extraversion. As with the SO, SI and SD according to
the transplantation periods in patients with HSCT, changes in taste
and loss of appetite were highest all the periods of transplantation. It
is offered that further development and evaluation research of effec-
tive diet programs for patients with HSCT are necessary.433
ENHANCING THE SAFETY OF HIGH RISK MEDICATION ADMINISTRATION
ON AN INPATIENT STEM CELL TRANSPLANT UNIT
Johnson, M., White, A., Jacob, R., Johnston, P. The University of Md
Anderson Cancer Center, Houston, TX
Background:Medication administration errors are an increasing
concern in health care. High dose chemotherapy, biologicmodifying
agents, and medications used in the prevention and treatment of
GVHD account for a portion of these errors. The effects of these
medication errors can be lethal when they are administered incor-
rectly. With the increasing use of agency and float pool staff, there
may be nurses administering these agents who are not familiar
with the correct procedure for administration or the side effects as-
sociatedwith them.The Joint Commission has identifiedmedication
safety as one of its 2009 National Patient Safety goals. Nine patient
safety solutions have been previously identified by the International
Steering Committee. These solutions are to be used as a guide in
evaluating and re-designing delivery of care to focus on prevention
of medication errors and safe medication administration. In imple-
menting these solutions into our model of care for our 52 bed impa-
tient Stem Cell Transplant and Cellular Therapy Unit, we have
identified the need for an additional measure to decrease the risk
of medication administration errors with those particular high risk
medications.
Interventions: A tool was developed to aid in the administration
of chemotherapy, biologic modifying agents, and medications used
in the prevention and treatment of GVHD. These tools included
the name of the drug, the tubing and filter to be used, the vital
sign schedule, the side effects, and any miscellaneous information
that needed to be included for each specific medication. The tool
was then placed in each of the chemotherapy preparation areas where
the nurses would be able to see and access the information easily.
Results: An evaluation tool was administered to the nurses on
SCTCT unit to determine if the tool was effectively making it easier
to access the correct information about the medications that they
were administering.
Recommendations:The creation of a chemotherapy/medication
chart on our inpatient SCTCT unit has assisted in decreasing the
number of medication errors as well as increasing the awareness of
nursing staff in regards to safe administration of these agents.434
UTILITY OF INSUFLONe CATHETERS AFTER PEDIATRIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION: TAKING THE PAIN OUT OF SUBCU-
TANEOUS INJECTIONS
Prokopiou, C., Koontz, S.E., Rosipal, N., Worth, L.L., Petropoulos, D.,
Kelly, S.S., Lee, D.A., Cooper, L.J.N. Children’s Cancer Hospital at the
University of Texas M. D. Anderson Cancer Center, Houston, TX
